Past year
All results
- All results
- Verbatim
The long-term follow-up of a large, pooled analysis of patients treated with tandem autologous versus autologous–allogeneic transplantation showed significantly longer overall survival with ASCT/RIC-allo-HSCT compared to tandem ASCT [9].
Dec 7, 2023
Jun 4, 2024 · Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up.
Apr 25, 2024 · MM patients who received autologous tandem allogeneic HSCT did not achieve better response compared to tandem autologous HSCT. In summary, compared to single ...
Nov 13, 2024 · Most importantly, in accordance with the existing data, there seems to be a long-term survival of up to 15 years in around 20% of patients after allo-SCT. Due ...
Sep 3, 2024 · The use of autologous stem cell transplantation (ASCT) in multiple myeloma (MM) is the standard of care in patients who are deemed transplantation eligible.
3 days ago · Tandem transplantation with an initial autologous hematopoietic cell transplant followed by reduced-intensity conditioning allogeneic hematopoietic cell.
Nov 4, 2024 · The patients who have relapsed after allo-SCT can experience long-term survival, suggesting a synergy between anti-myeloma drugs administered after allo-SCT ...
Apr 8, 2024 · Meta-analysis showed that compared to single autologous hematopoietic stem cell transplantation, tandem auto-. HSCT does not improve OS, EFS or efficacy in MM ...
Mar 4, 2024 · Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study ...
Feb 21, 2024 · Autologous Stem Cell Transplant for Multiple Myeloma: Impact of Eliminating Day of Rest on Incidence of Complications and Re-Admission Rate · Developing Practice ...